A Single Protein in the Brain's Memory Hub Drives the Compulsion to Seek Cocaine

About 24 percent of people who successfully stop using cocaine relapse to weekly use within a year. Another 18 percent return to treatment programs in the same window. These numbers are not evidence of weak character. They are, neuroscientists increasingly believe, the predictable output of a brain that has been physically reconfigured by the drug.

There is currently no FDA-approved medication to treat cocaine addiction. Opioid addiction has methadone and buprenorphine. Alcohol addiction has naltrexone. Cocaine has nothing - partly because the biology of cocaine dependence has been harder to pin down, and partly because the withdrawal from cocaine lacks the acute physical drama of opioid withdrawal, which has historically made cocaine addiction seem like a problem of willpower rather than pharmacology.

A study from Michigan State University, published in Science Advances and supported by the National Institutes of Health, identifies a specific molecular switch in the brain that appears necessary for cocaine to produce its lasting grip - and points toward a possible class of pharmaceutical targets.

The hippocampus connection

Cocaine's well-known mechanism involves the nucleus accumbens - the brain's reward center - which it floods with dopamine, producing a rush that the brain learns to associate with whatever preceded it. But addiction is not just about the reward; it is about the memories that trigger craving. That is where the hippocampus comes in.

The hippocampus is the brain's primary memory-forming structure. It talks constantly with the nucleus accumbens through a circuit that, under normal conditions, helps contextualize reward - associating specific places, people, and cues with positive or negative experiences. In cocaine addiction, this circuit appears to be fundamentally altered.

Andrew Eagle, a former postdoctoral researcher in A.J. Robison's lab and the paper's lead author, used a specialized form of CRISPR technology to examine a protein called DeltaFosB in this specific circuit. DeltaFosB is a transcription factor - a protein that binds to DNA and controls which genes are switched on or off. It accumulates over time in neurons exposed to repeated cocaine use, unlike many other molecular signals that peak and then decline.

Without this protein, cocaine loses its hold

Using mouse models, the researchers showed that DeltaFosB acts like a long-lasting molecular switch in the circuit between the nucleus accumbens and the hippocampus. The more cocaine a mouse received, the more DeltaFosB accumulated. As it accumulated, it changed how neurons in the circuit functioned - altering their electrical responses and the strength of their connections.

The critical test was what happened without it. When DeltaFosB was selectively removed from the reward-hippocampus circuit using CRISPR, cocaine no longer produced the same changes in brain activity or the same strong drive to seek the drug.

"This protein isn't just associated with these changes, it is necessary for them," Eagle said. "Without it, cocaine does not produce the same changes in brain activity or the same strong drive to seek out the drug."

"Addiction is a disease in the same sense as cancer," said senior author A.J. Robison, professor of neuroscience and physiology. "We need to find better treatments and help people who are addicted in the same sense that we need to find cures for cancer."

A second gene in the circuit

The team also identified a downstream gene controlled by DeltaFosB called calreticulin, which helps regulate how neurons communicate with each other. Their experiments showed that calreticulin contributes to the heightened drive to seek cocaine - providing a secondary molecular target that might be more tractable for drug development than DeltaFosB itself, which as a transcription factor is notoriously difficult to target directly.

Robison's lab is now partnering with researchers at the University of Texas Medical Branch in Galveston on a National Institute of Drug Abuse grant to develop compounds that regulate DeltaFosB's ability to bind to DNA. The idea is to find molecules that interrupt the transcriptional changes DeltaFosB produces without shutting it down entirely - a nuanced pharmacological challenge.

"If we could find the right kind of compound that works in the right way, that could potentially be a treatment for cocaine addiction," Robison said. "That's years away, but that's the long-term goal."

Sex differences, next

The current study used standard mouse models, and the team acknowledges that results in mice do not always translate directly to human biology - though humans and mice share many of the same genes and broadly similar neural circuit architectures.

One natural extension of the work is examining sex differences. Robison's lab plans to look at how hormones interact with these brain circuits, and whether cocaine affects the male and female brain differently. There is already epidemiological evidence that addiction risk and relapse patterns differ between men and women; the molecular basis for those differences remains poorly understood.

For now, the identification of DeltaFosB as a necessary - not merely correlative - driver of cocaine-induced circuit remodeling gives the field a clearer target than it had before.